INDIVIOR INC.
ST. PETERSBURG, FLORIDA

Indivior Inc., based out of Richmond, Virginia, has dedicated itself for over two decades to tackling the complex issue of addiction on a global scale. Founded as part of the Buprenorphine Business Group by Reckitt Benckiser in 1994, Indivior quickly became an influential name in innovating treatments for opioid use disorders and related conditions. Today, they operate across more than 40 countries, highlighting their extensive reach. The backbone of Indivior's mission is its patient-oriented approach, built on three key areas: driving product innovation; expanding access infrastructure to help patients better manage treatment; and building meaningful connections with essential stakeholders like governments, healthcare providers, and advocacy groups. Key partnerships include a 2014 collaboration with AntiOp, Inc., focused on developing a nasal spray for reversing opioid overdoses, as well as a licensing arrangement with XenoPort, Inc., which focuses on finding new solutions for alcohol use disorders. Since its establishment within Reckitt Benckiser Pharmaceuticals and its incorporation in September 2014, Indivior has witnessed pivotal moments, such as becoming publicly listed on the London Stock Exchange following a demerger. The leadership team-including Richard Simkin (Director), Ryan Preblick (Treasurer), and Mark W Crossley (Director)-is deeply committed to addressing unmet treatment needs within the intricate world of addiction treatment. Headquartered at 10710 Midlothian Turnpike in Richmond, Indivior remains steadfast in ensuring patient safety by encouraging open communication about product concerns or adverse events. For those interested in exploring how Indivior transforms health outcomes in addiction medicine through its range of products and services, visit [indivior.com](http://www.indivior.com).